Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 agonist (GLP). Dual GIP/GLP-1 agonists gained increasing attention as new agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials.
The protein sequence of Tirzepatide was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP. It has a role as a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a hypoglycemic agent, a gastric inhibitory polypeptide receptor agonist, and an incretin mimetic.
Tirzepatide 5 mg should be reconstituted with bacteriostatic water (BAC).
| Tirzepatide (LY3298176) | 5mg KIT, 20mg (1vial), 10mg (1 vial), 5mg (1vial) |
|---|
Related products
Metabolics
